Clinical Trials Browser

OTHER × Interventional × sparsentan × Clear all

NCT07224776 2026-02-27

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Phase 1 Not yet recruiting

Neoplasms, Proteinuria